Capsaicin-Induced Coughing

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform

D. Jackson - One of the best experts on this subject based on the ideXlab platform.

  • Dynamic modelling of a challenge-escalation cross-over study of treatment of Capsaicin-Induced Coughing.
    Statistics in Medicine, 2002
    Co-Authors: J. K. Lindsey, John Stevens, Byron Jones, D. Jackson
    Abstract:

    In a complex seven-period cross-over trial to study the effects of a drug in attenuating Capsaicin-Induced Coughing, counts of numbers of coughs were recorded 32 times in each period. Subjects were subjected to four escalating levels of capsaicin at each of one and five hours after treatment, with counts of coughs being recorded in four one-minute intervals at each level. Such longitudinal count studies often show considerable individual variability about any regression curve that might be fitted. We develop a non-linear autoregressive model for such count data that also allows for overdispersion. Copyright © 2002 John Wiley & Sons, Ltd.

J. K. Lindsey - One of the best experts on this subject based on the ideXlab platform.

  • Dynamic modelling of a challenge-escalation cross-over study of treatment of Capsaicin-Induced Coughing.
    Statistics in Medicine, 2002
    Co-Authors: J. K. Lindsey, John Stevens, Byron Jones, D. Jackson
    Abstract:

    In a complex seven-period cross-over trial to study the effects of a drug in attenuating Capsaicin-Induced Coughing, counts of numbers of coughs were recorded 32 times in each period. Subjects were subjected to four escalating levels of capsaicin at each of one and five hours after treatment, with counts of coughs being recorded in four one-minute intervals at each level. Such longitudinal count studies often show considerable individual variability about any regression curve that might be fitted. We develop a non-linear autoregressive model for such count data that also allows for overdispersion. Copyright © 2002 John Wiley & Sons, Ltd.

John Stevens - One of the best experts on this subject based on the ideXlab platform.

  • Dynamic modelling of a challenge-escalation cross-over study of treatment of Capsaicin-Induced Coughing.
    Statistics in Medicine, 2002
    Co-Authors: J. K. Lindsey, John Stevens, Byron Jones, D. Jackson
    Abstract:

    In a complex seven-period cross-over trial to study the effects of a drug in attenuating Capsaicin-Induced Coughing, counts of numbers of coughs were recorded 32 times in each period. Subjects were subjected to four escalating levels of capsaicin at each of one and five hours after treatment, with counts of coughs being recorded in four one-minute intervals at each level. Such longitudinal count studies often show considerable individual variability about any regression curve that might be fitted. We develop a non-linear autoregressive model for such count data that also allows for overdispersion. Copyright © 2002 John Wiley & Sons, Ltd.

Byron Jones - One of the best experts on this subject based on the ideXlab platform.

  • Dynamic modelling of a challenge-escalation cross-over study of treatment of Capsaicin-Induced Coughing.
    Statistics in Medicine, 2002
    Co-Authors: J. K. Lindsey, John Stevens, Byron Jones, D. Jackson
    Abstract:

    In a complex seven-period cross-over trial to study the effects of a drug in attenuating Capsaicin-Induced Coughing, counts of numbers of coughs were recorded 32 times in each period. Subjects were subjected to four escalating levels of capsaicin at each of one and five hours after treatment, with counts of coughs being recorded in four one-minute intervals at each level. Such longitudinal count studies often show considerable individual variability about any regression curve that might be fitted. We develop a non-linear autoregressive model for such count data that also allows for overdispersion. Copyright © 2002 John Wiley & Sons, Ltd.

Kian Fan Chung - One of the best experts on this subject based on the ideXlab platform.

  • Prostaglandin F2 alpha enhancement of capsaicin induced cough in man: modulation by beta 2 adrenergic and anticholinergic drugs.
    Thorax, 1990
    Co-Authors: G. M. Nichol, P. J. Barnes, Kian Fan Chung
    Abstract:

    The effect of inhaled prostaglandin (PG) F2 alpha on the response to the inhaled tussive agent capsaicin was investigated in normal subjects. Seven subjects inhaled three breaths of four doses of capsaicin (0.3, 0.6, 1.2, and 2.4 nmol) before and immediately after inhaling PGF2 alpha (0.1 mumol) or placebo (0.15M NaCl) on separate days. The numbers of capsaicin induced coughs were greater after PGF2 alpha (mean 42.3 coughs) than after 0.15M sodium chloride (30.1). Visual analogue scores (0-10 on a 10 cm continuous scale) showed that capsaicin was more irritant after PGF2 alpha than after saline. Total respiratory resistance (Rrs), measured by the forced oscillation technique, was unaltered throughout the study. A double blind, placebo controlled study of the effects of inhaled salbutamol (200 micrograms, 0.6 mumol) and ipratropium bromide (40 micrograms, 0.1 mumol) on cough induced by capsaicin (2.4 nmol) and by PGF2 alpha (0.1 mumol) and on PGF2 alpha augmented, capsaicin induced Coughing was performed in seven subjects. Neither drug had any effect on capsaicin induced Coughing. Salbutamol reduced Coughing due to PGF2 alpha (mean 7.7 coughs after salbutamol, 9.3 after placebo) but ipratropium bromide did not (mean 6.9 coughs after ipratropium bromide, 6.6 after placebo). Salbutamol also inhibited the augmentation of the capsaicin induced cough that followed inhalation of PGF2 alpha (mean augmentation 1.9 coughs after salbutamol, 4.1 after placebo), whereas ipratropium bromide did not (augmentation 1.7 coughs after ipratropium bromide, 2.7 after placebo). No changes in Rrs were seen after PGF2 alpha or either drug. Thus salbutamol reduces PGF2 alpha induced cough and the augmentation of capsaicin induced cough that follows PGF2 alpha.